Akira Suwa
Tokai University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Akira Suwa.
Modern Rheumatology | 2009
Tetsuya Takada; Michito Hirakata; Akira Suwa; Yuko Kaneko; Masataka Kuwana; Tadayuki Ishihara; Yasuo Ikeda
To elucidate the clinical and histopathological features associated with autoantibodies to the signal recognition particle (SRP), we have studied 23 Japanese patients with this specificity among 3,500 patients with polymyositis/dermatomyositis and other connective tissue diseases. Anti-SRP antibodies were determined based on analysis of RNA and protein components by immunoprecipitation assays. The pathological analysis was performed by using special stainings including alkaline phosphatase, myosin ATPase, and modified Gomori trichrome stainings. Twenty-one (92%) of these 23 patients had myositis, 8 of whom (38%) required cytotoxic agents or intravenous immunoglobulin therapy in addition to corticosteroid therapy. Four patients (16%) had rheumatoid arthritis, two of whom had no features of myositis. Muscle biopsy specimens of 11 patients were examined histologically in detail. All 11 had muscle fiber necrosis and/or regeneration, but only one had infiltration of inflammatory cells. Six of the 11 (55%) patients showed type I fiber predominance by ATPase staining, while eight control myositis patients without anti-SRP antibodies did not. There was no correlation of other neurogenic features in histology with the presence of anti-SRP antibodies. These studies suggest that anti-SRP autoantibodies are most likely to be related to myopathies that are resistant to corticosteroid therapy and without inflammation histopathologically.
Journal of Clinical Investigation | 1996
Akira Suwa; Michito Hirakata; Yoshihiko Takeda; Yutaka Okano; Tsuneyo Mimori; Shinichi Inada; Fumiaki Watanabe; Hirobumi Teraoka; William S. Dynan; John A. Hardin
DNA-dependent protein kinase (DNA-PK) is an important nuclear enzyme which consists of a catalytic subunit known as DNA-PKcs and a regulatory component identified as the Ku autoantigen. In the present study, we surveyed 312 patients in a search for this specificity. 10 sera immunoprecipitated a large polypeptide which exactly comigrated with DNA-PKcs in SDS-PAGE. Immunoblot analysis demonstrated that this polypeptide was recognizable by a rabbit antiserum specific for DNA-PKcs. Although the patient sera did not bind to biochemically purified DNA-PKcs in immunoblots or ELISA, they were able to deplete DNA-PK catalytic activity from extracts of HeLa cells in a dose-dependent manner. We conclude that these antibodies should be useful probes for studies which aim to define the role of DNA-PK in cells. Since six sera simultaneously contained antibodies to the Ku protein, these studies suggest that relatively intact forms of DNA-PK complex act as autoantigenic particles in selected patients.
Biotechnology Progress | 2008
Takahiro Matsudaira; Saki Tsuzuki; Akira Wada; Akira Suwa; Hitoshi Kohsaka; Maiko Tomida; Yoshihiro Ito
Autoimmune diseases such as rheumatoid arthritis, multiple sclerosis, and autoimmune diabetes are characterized by the production of autoantibodies that serve as useful diagnostic markers, surrogate markers, and prognostic factors. We devised an in vitro system to detect these clinically pivotal autoantibodies using a photoimmobilized autoantigen microarray. Photoimmobilization was useful for preparing the autoantigen microarray, where autoantigens are covalently immobilized on a plate, because it does not require specific functional groups of the autoantigens and any organic material can be immobilized by a radical reaction induced by photoirradiation. Here, we prepared the microarray using a very convenient method. Aqueous solutions of each autoantigen were mixed with a polymer of poly(ethylene glycol) methacrylate and a photoreactive crosslinker, and the mixtures were microspotted on a plate and dried in air. Finally, the plate was irradiated with an ultraviolet lamp to obtain immobilization. In the assay, patient serum was added to the microarray plate. Antigen‐specific IgG adsorbed on the microspotted autoantigen was detected by peroxidase‐conjugated anti‐IgG antibody. The chemical luminescence intensities of the substrate decomposed by the peroxidase were detected with a sensitive CCD camera. All autoantigens were immobilized stably by this method and used to screen antigen‐specific IgG. In addition, the plate was covered with a polydimethylsiloxane sheet containing microchannels and automated measurement was carried out.
Lupus | 2010
Yuko Kaneko; Akira Suwa; M. Hirakata; Yasuo Ikeda; Masataka Kuwana
The reactivities to individual U1 small nuclear ribonucleoprotein (snRNP) components and their relationship to clinical features in patients with anti-U1 snRNP antibodies were examined. We evaluated 114 patients with connective tissue disease whose sera were positive for anti-U1 snRNP antibodies, but negative for anti-Sm antibodies. Antibodies to the U1 snRNP polypeptides 70K, A, and C were detected using subunit-specific enzyme-linked immunosorbent assays and antibodies to U1 small nuclear RNA (snRNA) were identified by an immunoprecipitation assay using deproteinized HeLa cell extracts. The clinical features were retrospectively obtained by chart review and prospectively collected after study entry. The pattern of antibody reactivities to U1 snRNP components varied among patients. The frequency of anti-70K, anti-A, anti-C, and anti-U1 snRNA antibodies was 60%, 86%, 74%, and 46%, respectively. There was no relationship between each reactivity and the clinical findings, but the presence of reactivities to increasing numbers of U1 snRNP components was correlated with sclerodactyly, shortness of the sublingual frenulum, esophageal dysfunction, and a lack of persistent proteinurea (p < 0.05 for all comparisons). The detection of autoantibody reactivities to individual components of the U1 snRNP particle is potentially useful for predicting the clinical course in patients with connective tissue disease and anti-U1 snRNP antibodies. Lupus (2010) 19, 307—312.
Proceedings of the National Academy of Sciences of the United States of America | 1994
Akira Suwa; Michito Hirakata; Yoshihiko Takeda; Stephen A. Jesch; Tsuneyo Mimori; John A. Hardin
Proceedings of the National Academy of Sciences of the United States of America | 1990
Tsuneyo Mimori; Y Ohosone; N Hama; Akira Suwa; Masashi Akizuki; M Homma; A J Griffith; John A. Hardin
Arthritis & Rheumatism | 2007
Michito Hirakata; Akira Suwa; Tetsuya Takada; Shinji Sato; Sonoko Nagai; Ekkehard Genth; Yeong Wook Song; Tsuneyo Mimori; Ira N. Targoff
The Journal of Rheumatology | 2008
Shinji Sato; Tetsuya Takada; Yumiko Katsuki; Noriko Kimura; Yuko Kaneko; Akira Suwa; Michito Hirakata; Masataka Kuwana
Arthritis & Rheumatism | 1996
Michito Hirakata; Akira Suwa; Yoshihiko Takeda; Yasuo Matsuoka; Shoichiro Irimajiri; Ira N. Targoff; John A. Hardin; Joe Craft
Clinical and Experimental Rheumatology | 2000
Takaki Nojima; M. Hirakata; Shinichi Sato; Takao Fujii; Akira Suwa; Tsuneyo Mimori; Yasuo Ikeda